Indications, dosage, usage, price and precautions of the new leukemia drug ensidipine

Indications:

Enasidenib is an oral small molecule inhibitor suitable for the treatment of patients with specific types of acute myeloid leukemia (AML). It is mainly used to treat AML patients who carry mutations in the IDH2 gene. This gene mutation is one of the common abnormalities found in some patients with AML.

Dosage and usage:

The dosage and usage of ensidipine should be determined by the doctor based on the patient's condition and individual differences. Generally speaking, the standard dose is taken orally once daily, and it is recommended to take it after meals to minimize the occurrence of gastrointestinal discomfort. The usual dose is 100mg (mg), but sometimes the doctor may adjust the dose depending on the patient's condition. The treatment cycle is usually 28 days, and patients need to continue taking ensidipine until the doctor determines the discontinuation time.

Price:

Ensidipine has not yet obtained marketing approval in China, which means that domestic patients cannot purchase the drug directly and must purchase it through overseas channels. Abroad, relatively low-priced drug options are generic drugs, especially those produced in Laos and Bangladesh, which sell for between 2,000 and 4,000 yuan. It is worth mentioning that these generic drugs are very close to the original drugs in terms of pharmaceutical ingredients.

Notes:

1.Monitoring and managing side effects: During ensidipine treatment, patients need to be monitored and managed regularly by their doctors to ensure the effectiveness and safety of the treatment. Doctors may order blood tests, liver function tests, and more to monitor the patient's condition and medication side effects.

2.Drug Interactions: Before using ensidipine, patients should inform their doctor about all medications they are taking, including prescription drugs, over-the-counter drugs, supplements, and herbal medicines, because some drugs may interact with ensidipine, affecting its efficacy or increasing the risk of adverse reactions.

3.Digestive tract reactions: Ensidipine may cause gastrointestinal discomfort, such as nausea, vomiting, diarrhea, etc. Patients should use medications under the guidance of their doctors and follow the correct medication regimen to reduce the occurrence of these adverse reactions.

4.Pregnancy and lactation: Ensidipine may have adverse effects on the fetus, so pregnant women should avoid using this drug. For women who are breastfeeding, the use of ensidipine should be carefully considered and whether to stop breastfeeding should be decided on the advice of a doctor.

5.Bleeding risk: Ensidipine may increase the risk of bleeding. Patients should avoid using platelet inhibitors and other drugs that increase the risk of bleeding during treatment, and promptly report to their doctor if abnormal bleeding symptoms occur.

6.Liver function monitoring: Because ensidipine may have adverse effects on the liver, patients need to undergo regular liver function monitoring during treatment. If symptoms of abnormal liver function occur, such as jaundice, pain in the liver area, etc., you should report it to your doctor immediately.

In summary, as a new type of AML treatment drug, ensidipine’s indications, dosage, price and precautions must be determined and followed under the guidance of a doctor. Patients should closely cooperate with the doctor's treatment plan and undergo regular monitoring and management to ensure the effectiveness and safety of the treatment.